Abstract Number: 2360 • 2014 ACR/ARHP Annual Meeting
Glucocorticoids and Vascular Function in Arthritis: Benefic or Deleterious Effects? Study in Rat
Background/Purpose: Rheumatoid Arthritis (RA) is associated to an increase of cardiovascular (CV) risk explained in part by an accelerated atherosclerosis as a consequence of endothelial…Abstract Number: 2361 • 2014 ACR/ARHP Annual Meeting
the Role of CD146 in the Therapeutic Potential of Mesenchymal Stem Cells in Favor of CD146+ Cells for Experimental Arthritis
Background/Purpose: To illustrate whether the subtypes of mesenchymal stem cells (MSCs) have different cellular characteristics and therapeutic potentials, we separated CD146+/- mesenchymal stem cells and…Abstract Number: 2362 • 2014 ACR/ARHP Annual Meeting
Enhanced Efficacy of Dexamethose with Synovial Fibroblast Targeted Micelles in a Collagen-Induced Arthritis Mouse Model
Background/Purpose: A number of conventional, disease modifying anti-rheumatic drugs (DMARDs) are associated with severe side effects due to non-specific targeting and impaired immune function. To…Abstract Number: 2363 • 2014 ACR/ARHP Annual Meeting
Leucine-Rich Alpha-2 Glycoprotein Is a Potential Disease Activity Marker Under IL-6 Suppression in Autoimmune Arthritis
Background/Purpose C-reactive protein (CRP) is frequently used to evaluate inflammation in patients with rheumatoid arthritis (RA). However, CRP is normalized when IL-6 function is potently…Abstract Number: 2364 • 2014 ACR/ARHP Annual Meeting
PET-CT Imaging of Joints: A Quantitative Tool for Developing Novel Anti-Inflammatory Drugs
Background/Purpose: Mouse collagen induced arthritis (CIA) is the most commonly used preclinical model to screen new drug candidates for inflammatory arthritis. The conventional read out…Abstract Number: 2365 • 2014 ACR/ARHP Annual Meeting
Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Rheumatoid Arthritis Therapy with Etanercept
Background/Purpose: To evaluate the comparative effects of a pharmaceutical industry decision guide (Pharm Booklet) and International Patient Decision Aids Standard (IPDAS) compliant patient decision aids…Abstract Number: 2366 • 2014 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort
Background/Purpose: MTX is the cornerstone of RA treatment, although limitations of systemic exposure of oral MTX may affect its efficacy. Subcutaneous (SC) MTX has greater…Abstract Number: 2367 • 2014 ACR/ARHP Annual Meeting
Physician Awareness of Suboptimal Patient Adherence to MTX: Results from a Large U.S. Rheumatoid Arthritis Registry
Background/Purpose: Most rheumatoid arthritis (RA) registries capture information about medication use using data captured at office visits. The extent to which this information may be…Abstract Number: 2368 • 2014 ACR/ARHP Annual Meeting
Impact of Physicians’ Adherence to Treat-to-Target Strategy on Outcomes in Early Rheumatoid Arthritis
Background/Purpose We have previously shown that in early rheumatoid arthritis (RA) remission targeted, intensive combination treatment, regardless of initial infliximab, results in remission in most…Abstract Number: 2369 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis -á Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…Abstract Number: 2370 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis Factor α Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…Abstract Number: 2371 • 2014 ACR/ARHP Annual Meeting
Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra
Background/Purpose: The biological disease-modifying anti-rheumatic drugs (bDMARDs) should be used for the treatment of rheumatoid arthritis (RA) in combination with conventional synthetic DMARDs (csDMARDs). However…Abstract Number: 2372 • 2014 ACR/ARHP Annual Meeting
Fatigue and Related Factors in Patients with Rheumatoid Arthritis Treated with Tocilizumab in Daily Clinical Setting
Background/Purpose: Fatigue in RA possibly resulting from alterations in the HPA axis like occurs with others RA symptoms as morning stiffness, and mood and sleep…Abstract Number: 2333 • 2014 ACR/ARHP Annual Meeting
The Natural Use of Activity Pacing in Daily Life Does Not Result in Lower Symptoms in Osteoarthritis
Background/Purpose: To examine the how individuals naturally use the behavioral strategy of activity pacing in daily life and how its usage relates to pain and…Abstract Number: 2334 • 2014 ACR/ARHP Annual Meeting
Understanding the Experiences of Rural Community-Dwelling Older Adults in Using a New DVD-Delivered Otago Exercise Programme
Background/Purpose: Arthritis is known to increase the risk of injurious falls. The home-based Otago Exercise Programme (OEP) has been shown to reduce the occurrence of…
ACR Meeting Abstracts